Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Evaluation of the Proximal Form of Precontoured Sectional Matrix in Complex Proximal Posterior Restorations

NCT07227688 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-01-01
Last updated
2025-11-13

Condition(s) studied

Complex Caries

Investigational drug(s) / intervention(s)

BioFit Posterior Matrix SystemSaddle system (TOR VM, Moscow, Russia)Sectional matrix: Classic ring system (TOR VM, Moscow, Russia)

BioFit Posterior Matrix System: precontoured sectional matrix system

Saddle system (TOR VM, Moscow, Russia): precontoured sectional matrix systems

Sectional matrix: Classic ring system (TOR VM, Moscow, Russia): precontoured sectional matrix systems

Study summary

Evaluation of the proximal anatomical form quality of different precontoured sectional matrix systems in complex proximal posterior resin composite restorations using Fédération Dentaire Internationale' (FDI) clinical criteria for the evaluation of direct and indirect restorations

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with posterior complex class II cavities to be restored with resin composite restorations. * 18 - 45 years. * Males or Females. * Good oral hygiene. * Co-operative patients approving to participate in the study. Exclusion Criteria: * Poor oral hygiene. * Allergic history concerning methacrylates * Evidence of parafunctional habits. * Presence of malalignment of teeth

Primary outcome measure(s)

  • Number of participants with a change in the proximal anatomical form using (FDI) World Dental Federation clinical criteria for the evaluation of direct and indirect restorations — Immediately after restoration placement at the baseline
    1. Proximal contact point with the aid of visual examination and 25-/50-/100-μm metal blades. 2. Form and contour utilizing visual examination and radiographic assessment. For each criterion, one score will be chosen from 5 scores (excellent, good, satisfactory, unsatisfactory \& poor).

Trial sites (1)

FacilityCityRegionStatus
Cairo University Giza GZ
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07227688 on ClinicalTrials.gov ↗ ← All trials in Egypt